


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on August 12, 2004.

Caroline Wei-Berk 45,203  
Name of Attorney/Agent Registration No.  
Signature of Attorney or Agent

1/2004



P&G Case 9128ML

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in the application of

Scheper et al.

Serial No. 10/714,785

Filed November 17, 2003

:

: Confirmation No. 2437

: Group Art Unit 1751

: Examiner

For Compositions Comprising Glycol Ether Solvents and Methods Employing Same

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. ☐ 37 C.F.R. §1.97(b)(1) - U.S. Direct (use when filing IDS with nonprovisional patent application, or with Request for Continued Examination (RCE); or within 3 months of filing a nonprovisional patent application)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(1), is being filed with the patent application, with a Request for Continued Examination or within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. ☒ **37 C.F.R. §1.97(b)(3) - (use when filing IDS more than 3 months after filing a nonprovisional patent application, but prior to receipt of first Office Action)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

3. ☐ **37 C.F.R. §1.97(b)(4) - (use when filing IDS prior to receipt of first Office Action after the filing of a Request for Continued Examination (RCE) under §1.114)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(4). Applicants have not received a first Office Action after filing a Request For Continued Examination (RCE). Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

4. ☐ **37 C.F.R. §1.97(c) with fee payment - (use when filing IDS after receipt of first Office Action, and before receipt of Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

5. ☐ **Information to be Considered with Continued Prosecution Application (CPA) Filing (use when filing IDS with a Continued Prosecution Application (CPA) for Design Case)**. This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 C.F.R. 1.53(d).

**ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:**

☐ (1) (For use with applications filed prior to or on June 30, 2003.) Copies of the cited documents are enclosed.

OR

☒ (2) (For use with applications filed after June 30, 2003.) In accordance with 37 C.F.R. §1.98(a)(2), Applicants are submitting copies of foreign patent documents and non-patent literature.

OR

☐ (3) All of the cited references were previously cited by or submitted to the USPTO in prior application Case No. \_\_\_\_, U.S. Patent Application Serial No. \_\_, filed \_\_. Applicants claim priority to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

OR

☐ (4) Copies of all said documents, except Cite Numbers \_\_\_\_, were submitted and considered in parent application U.S. Patent Application Serial No. \_\_\_\_, filed \_\_\_\_\_. Applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies of references not previously submitted are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

☐ (5) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is provided.

☒ (6) Applicants also respectfully request the Examiner to consider and make of record the co-pending applications listed on the attached page.

☐ Additional information is attached.

Respectfully submitted,

By Caroline Wei-Berk  
 Caroline Wei-Berk  
 Attorney or Agent for Applicant(s)  
 Registration No. 45,203  
 (513) 627-0352

Date: August 12, 2004  
 Customer No. 27752  
 (IDS.doc) (Last Revised 05/27/04)

### **CO-PENDING U.S. APPLICATIONS**

Entire copies of all co-pending applications (or the portion of the application and claims that caused it to be cited) must be sent with the IDS (see 37 CFR 1.98(a)(2)(iii))

<u>Atty. Docket No.</u>	<u>Serial Number</u>	<u>Inventor(s)</u>	<u>Filing Date</u>
9127ML	10/714,783	Scheper	11/17/2003
8643C	10/307,744	France	12/02/2002
8692M	10/238,292	Scheper	09/10/2002
8823	10/321,262	Scheper	12/17/2002
9304	10/876,191	Haught	06/24/2004

[Only applications that remain pending at the time of submitting this IDS should be listed here. For applications in which patents have issued, the granted patents should be listed on Form PTO/SB08.]


Please type a plus sign (+) inside this box → [+]

PTO/SB08A (1 0-01)

Approved for use through 10/31/2002 OMB 0651-0031  
Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p style="text-align: center;">Substitute for form 1449A/PTO</p> <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(use as many sheets as necessary)</p> <p style="text-align: center;">SHEET 1 of 3</p>	<p style="text-align: center;"><b>COMPLETE IF KNOWN</b></p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 60%;">Application Number</td> <td>10/714,785</td> </tr> <tr> <td>Confirmation Number</td> <td>2437</td> </tr> <tr> <td>Filing Date</td> <td>November 17, 2003</td> </tr> <tr> <td>First Named Inventor</td> <td>Scheper</td> </tr> <tr> <td>Group Art Unit</td> <td>1751</td> </tr> <tr> <td>Examiner Name</td> <td>TBD</td> </tr> <tr> <td>Attorney Docket Number</td> <td>9128ML</td> </tr> </table>	Application Number	10/714,785	Confirmation Number	2437	Filing Date	November 17, 2003	First Named Inventor	Scheper	Group Art Unit	1751	Examiner Name	TBD	Attorney Docket Number	9128ML
Application Number	10/714,785														
Confirmation Number	2437														
Filing Date	November 17, 2003														
First Named Inventor	Scheper														
Group Art Unit	1751														
Examiner Name	TBD														
Attorney Docket Number	9128ML														



### U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	DOCUMENT NUMBER Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	US-3,663,160	05/16/1972	Stone et al.	
	2	US-3,840,340	10/08/1974	McKnight	
	3	US-4,102,824	07/25/1978	Mizutani Et al.	
	4	US-4,639,321	01/27/1987	Barrat et al.	
	5	US-4,685,930	08/11/1987	Kasprzak et al.	
	6	US-4,708,807	11/24/1987	Kemerer et al.	
	7	US-4,489,455	12/25/1984	Spendel	
	8	US-4,489,574	12/25/1984	Spendel	
	9	US-5,191,668	03/09/1998	Euler et al.	
	10	US-5,191,669	03/09/1993	Euler et al.	
	11	US-5,219,370	06/15/1993	Farrington et al.	
	12	US-5,344,718	08/10/1993	Hardaway et al.	
	13	US-5,345,637	09/13/1994	Pastryk et al.	
	14	US-5,461,742	10/31/1995	Pasad et al.	
	15	US-5,595,071	01/21/1997	Pasad et al.	
	16	US-5,705,562	01/06/1998	Hill et al.	
	17	US-5,707,613	01/13/1998	Hill et al.	
	18	US-5,628,833	05/13/1997	McCormack et al.	
	19	US-5,865,852	02/02/1999	Berndt et al.	
	20	US-5,876,510	03/02/1999	Kuemin et al.	
	21	US-5,883,065	03/16/1999	Swift, II et al.	
	22	US-5,888,250	03/30/1999	Hayday et al.	
	23	US-5,912,222	06/15/1999	Thomas et al.	
	24	US-5,913,222	06/15/1999	Thomas et al.	
	25	US-5,942,007	08/24/1999	Berndt et al.	
	26	US-5,977,040	11/02/1999	Inada et al.	
	27	US-5,985,810	11/16/1999	Inada et al.	
	28	US-6,013,683	01/11/2000	Hill et al.	
	29	US-6,042,617	03/28/2000	Berndt et al.	
	30	US-6042,618	03/28/2000	Berndt et al.	
	31	US-6,056,789	05/02/2000	Berndt et al.	
	32	US-6,059,845	05/09/2000	Berndt et al.	
	33	US-6,060,546	05/09/2000	Powell et al.	
	34	US-6,063,135	05/16/2000	Berndt et al.	
	35	US-6,136,766	10/24/2000	Inada et al.	
	36	US-6,156,074	12/5/2000	Hayday et al.	
	37	US-6,177,399	01/23/2001	Mei et al.	
	38	US-6,258,130 B1	07/10/2001	Murphy et al.	
	39	US-6,273,919 B1	08/14/2001	Hayday et al.	
	40	US-6,309,425 B1	10/30/2001	Murphy et al.	
	41	US-6,348,441	02/19/2002	Aiken, III et al.	
	42	US-6,368,359	04/09/2002	Perry et al.	
	43	US-6,626,530	9/30/2003	Snow et al.	
	44	US20010020308	09/13/2001	Murphy et al.	
	45	US20010034912	11/01/2001	Kilgour et al.	
	46	US20020004953 A1	01/17/2002	Perry et al.	
	47	US20020115582	08/22/2002	Perry et al.	
	48	US20020174493	11/28/2002	Perry et al.	

	49	US2002083531 A1	04/04/2002	Hayday	
	50	US20030091749 A1	05/15/2003	France et al.	

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	FOREIGN PATENT DOCUMENT			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	51	EP	0982 023 A2		03/01/2000	General Electric Co.		
	52	EP	1 041 189 A1		10/04/2000	General Electric Co.		
	53	EP	1 043 443 A1		10/11/2000	General Electric Co.		
	54	EP	1 092 803 A1		04/18/2001	Uniliver NV		
	55	DE	37 39 711 A1		06/08/1989	Chemische et al.	English Translation attached	
	56	WO	99/58753 A1		11/18/1999	Notetry Limited		
	57	WO	00/04221 A1		01/27/2000	Berndt et al.		
	58	WO	00/04222 A1		01/27/2000	Greeneearth Cleaning		
	59	WO	00/63340 A1		10/26/2000	Dow Chemical et al.		
	60	WO	01/40567 A1		06/07/2001	Unilever et al.		
	61	WO	01/55497 A1		08/02/2001	Custom Cleaner, Inc.		
	62	WO	01/90474 A1		11/29/2001	Unilever		
	63	WO	01/94678 A1		12/13/2001	Procter & Gamble		
	64	WO	01/94681 A1		12/13/2001	Procter & Gamble		
	65	WO	01/94684 A1		12/13/2001	Procter & Gamble		
	66	WO	01/96513 A1		12/20/2001	Rynex Holdings		
	67	WO	02/46517 A1		06/13/2002	General Electric		
	68	WO	02/48447 A1		06/20/2002	General Electric		
	69	WO	02/50366 A1		06/27/2002	General Electric		
	70	WO	02/77356 A1		10/03/2002	General Electric		
	71	WO	02/083828 A1		10/24/2002	Playtex Products		
	72	WO	02/97024 A1		05/12/2002	Azuma et al.	English Translation attached	
	73	JP	2000-290689 A		10/17/2000	Shin Etsu Chem et al.	English Translation attached	
	74	JP	05051598 A2		03/02/1993	Ahahi Chem	English abstract attached	
	75	JP	61098798 A2		05/17/1986	Lion Corp	English abstract attached	
	76	JP	630 63799 A2		03/22/1988	Lion Corp	English abstract attached	
	77	JP	63046300 A2		02/27/1988	Lion Corp	English Abstract attached	
	78	JP	2000-144175 A2		05/26/2000	Lion Corp	English Abstract Attached	
	79	EP	479,146 B1		12/18/1996	Mihama Corp		

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>6</sup>
<b>EXAMINER</b>			<b>DATE CONSIDERED</b>

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.